Minocycline 100mg ( DrugBank: Minocycline )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04291456 (ClinicalTrials.gov) | January 31, 2020 | 18/11/2019 | Minocycline in MS: Confirmation of Benefit | Open-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment Benefit | Multiple Sclerosis;Clinically Isolated Syndrome | Drug: Minocycline 100mg | University of Calgary | Hotchkiss Brain Institute, University of Calgary | Recruiting | 18 Years | 60 Years | All | 148 | Phase 3 | Canada |